+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Central Nervous System Drugs Market - Global Forecast 2026-2032- Product Image
Central Nervous System Drugs Market - Global Forecast 2026-2032- Product Image
Sale

Central Nervous System Drugs Market - Global Forecast 2026-2032

  • Report

  • 186 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 6010786
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Central Nervous System Drugs Market is projected to reach USD 34.16 Billion in 2026. It is expected to continue growing at a CAGR of 10.85%, reaching USD 63.59 Billion by 2032.

Central nervous system drugs remain a critical pillar of global healthcare because neurological and psychiatric disorders represent a large, persistent, and clinically complex disease burden. The World Health Organization identifies neurological disorders as a leading cause of disability worldwide, while conditions such as depression, epilepsy, migraine, multiple sclerosis, Parkinson’s disease, Alzheimer’s disease, schizophrenia, and neuropathic pain continue to drive sustained treatment need.

The CNS drugs landscape is shaped by high unmet need, extended development timelines, stringent safety monitoring, and evolving standards for patient-centered outcomes. Momentum is supported by aging populations, wider diagnosis of mental health conditions, improved neuroimaging and biomarker use, and expanding access to specialty medicines. At the same time, payers and regulators are demanding clearer evidence of meaningful clinical benefit, durable response, functional improvement, and real-world safety.

Transformative Shifts in the CNS Drugs Landscape

The CNS drugs industry is moving from broad symptomatic treatment toward precision neurology and psychiatry. Advances in genetics, cerebrospinal fluid biomarkers, blood-based biomarkers, digital phenotyping, and imaging are improving patient stratification in diseases where heterogeneity has historically contributed to high trial failure rates.

Transformative shifts are also visible in therapeutic modalities. Small molecules continue to dominate many CNS categories due to blood-brain barrier considerations, but biologics, antisense oligonucleotides, gene therapies, radioligand approaches, neurostimulation-adjacent care models, and disease-modifying therapies are expanding clinical possibilities. Regulatory attention to accelerated pathways, post-marketing evidence, risk evaluation strategies, and patient-reported outcomes is reshaping how innovators design trials and commercialize CNS treatments.

Cumulative Impact of Artificial Intelligence on CNS Drug Development

Artificial intelligence is becoming cumulative in its impact across the CNS drugs value chain rather than functioning as a single-point tool. AI-enabled target discovery, protein-structure modeling, compound screening, and multi-omics analysis are helping researchers evaluate biological pathways linked to neurodegeneration, neuroinflammation, synaptic function, seizure biology, pain signaling, and psychiatric disease mechanisms.

In clinical development, machine learning supports site selection, patient matching, signal detection, adverse-event monitoring, imaging interpretation, and real-world evidence generation. CNS trials are particularly suited for AI augmentation because they often rely on complex clinical scales, imaging datasets, wearable-derived mobility data, speech patterns, sleep signals, cognitive assessments, and electronic health records. However, industry leaders must pair AI adoption with model validation, bias assessment, regulatory documentation, data privacy controls, cybersecurity safeguards, and clinical interpretability.

Key Regional Insights for CNS Drugs

North America remains a leading CNS drugs region due to advanced research infrastructure, high specialty medicine adoption, extensive clinical trial networks, and strong regulatory engagement through the U.S. Food and Drug Administration and Health Canada. The region benefits from broad neurology and psychiatry care capacity, active academic research centers, and growing use of real-world evidence to evaluate treatment safety and outcomes. Europe is similarly influential, supported by the European Medicines Agency, national reimbursement systems, large academic neurology networks, and rising investment in neurodegenerative disease research. Across Europe, health technology assessment bodies continue to place strong emphasis on comparative effectiveness, long-term safety, and demonstrable patient benefit.

Asia-Pacific is gaining strategic importance as China, Japan, India, South Korea, and Australia expand clinical trial participation, domestic innovation, and access to psychiatric and neurological care. The region’s aging populations, expanding insurance coverage, and improving specialist infrastructure are increasing attention to Alzheimer’s disease, Parkinson’s disease, epilepsy, depression, migraine, and sleep disorders. Latin America shows improving demand for epilepsy, depression, migraine, and pain therapies, although reimbursement variability, diagnosis gaps, and uneven specialist access remain key constraints. The Middle East is increasing specialty care capacity in Gulf health systems through tertiary hospitals, digital health investment, and national mental health initiatives, while Africa presents long-term access opportunities as neurological diagnosis, mental health policy, workforce training, and essential medicine availability improve.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO

The European Union provides one of the most structured regulatory and health technology assessment environments for CNS drugs, with growing emphasis on comparative effectiveness, pharmacovigilance, safety surveillance, and equitable access across member states. The G7 countries anchor much of the world’s CNS research funding, pharmaceutical innovation, advanced care delivery, and regulatory science, making them central to adoption of disease-modifying therapies, specialty neurology treatments, and evidence-based mental health pharmacotherapy.

BRICS countries are increasingly important for patient diversity in clinical research, manufacturing capabilities, treatment access expansion, and healthcare infrastructure development, especially in China, India, and Brazil. ASEAN markets are improving neurological and mental healthcare infrastructure, with demand shaped by rising noncommunicable disease awareness, expanding hospital networks, and heterogeneous reimbursement and specialist availability. GCC countries are investing in tertiary care, digital health, rare disease programs, and specialty treatment access, supporting greater demand for advanced CNS therapies. NATO economies overlap significantly with high-income pharmaceutical markets where medicine supply resilience, strategic health security, cold-chain reliability, and continuity of care are receiving greater policy attention.

Key Country Insights for Priority CNS Drug Markets

The United States leads global CNS drug commercialization, clinical development, regulatory innovation, and premium specialty adoption, supported by deep capital markets, large clinical trial networks, and established Food and Drug Administration pathways. Canada emphasizes evidence-based reimbursement, health technology assessment, and access management, while Mexico and Brazil represent important Latin American markets where public and private systems shape uptake of epilepsy, psychiatric, migraine, and pain therapies. Brazil’s unified public health system and local regulatory framework support broad public health relevance, while Mexico’s mixed healthcare structure creates differentiated access dynamics across institutional and private channels.

In Europe, the United Kingdom, Germany, France, Italy, and Spain are major CNS drug markets with strong clinical expertise, neurology research centers, and established psychiatric care pathways, although reimbursement timelines and assessment criteria vary by country. Germany’s early benefit assessment process, the United Kingdom’s cost-effectiveness evaluation, and France’s clinical benefit review systems influence CNS launch strategies, while Italy and Spain balance regional access pathways with national reimbursement frameworks. Russia maintains domestic demand amid geopolitical and supply-chain complexity. China is accelerating CNS innovation and regulatory modernization, India combines a large patient base with strong generics manufacturing and expanding mental health awareness, Japan has high neurodegenerative disease relevance due to population aging, Australia offers sophisticated trial capacity and reimbursement evaluation, and South Korea is advancing biopharmaceutical innovation, digital health adoption, and specialty care access.

Actionable Recommendations for CNS Drug Industry Leaders

Industry leaders should prioritize differentiated clinical endpoints, biomarker-supported trial designs, and real-world evidence strategies that demonstrate functional improvement, safety, durability of response, and meaningful patient outcomes. CNS developers can improve trial productivity by using adaptive designs, decentralized assessment tools, digital biomarkers, validated rating scales, improved patient stratification, and earlier engagement with regulators on evidence expectations.

Commercial teams should align early with payers, clinicians, caregivers, and patient advocacy groups to define value in terms of disease progression, relapse reduction, cognition, mobility, seizure control, pain reduction, quality of life, caregiver burden, adherence, and healthcare resource utilization. Supply-chain resilience, pharmacovigilance excellence, inclusive trial recruitment, lifecycle evidence generation, and responsible AI governance should be treated as board-level priorities for sustainable CNS drug leadership.

Research Methodology

This executive summary is developed through secondary research using publicly available and verifiable sources, including health authorities, peer-reviewed biomedical literature, regulatory agency communications, clinical trial registries, public policy documents, and international health organizations. Priority was given to sources such as the World Health Organization, U.S. Food and Drug Administration, European Medicines Agency, National Institutes of Health, Organisation for Economic Co-operation and Development, national health agencies, and recognized medical journals.

The analysis synthesizes disease burden, regulatory trends, technology shifts, clinical development patterns, regional access dynamics, artificial intelligence adoption, and strategic implications. Insights are validated through triangulation across multiple data sources and presented in an structure for decision-makers evaluating the central nervous system drugs market, without relying on market sizing, market share, or forecast estimates.

Conclusion

The CNS drugs market is entering a more evidence-intensive and technology-enabled phase. Rising neurological and psychiatric disease burden, aging demographics, diagnostic advances, and growing use of biomarkers are creating opportunities for therapies that deliver measurable clinical benefit across neurology, psychiatry, pain management, and neurodegenerative care.

Success will depend on scientific differentiation, trial execution, regulatory credibility, market access planning, pharmacovigilance strength, and ethical use of artificial intelligence. Organizations that connect innovation with real-world patient needs, equitable access, and durable clinical outcomes will be best positioned to shape the next era of central nervous system therapeutics.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Central Nervous System Drugs Market, by Drug Class
7.1. Introduction
7.2. Analgesic
7.2.1. Non-Opioid Analgesic
7.2.2. Opioid Analgesic
7.3. Antidepressant
7.4. Antiepileptic
7.4.1. Calcium Channel Blocker
7.4.2. Gaba Enhancer
7.4.3. Glutamate Inhibitor
7.4.4. Sodium Channel Blocker
7.5. Antipsychotic
7.5.1. Atypical
7.5.2. Typical
7.6. Anxiolytic
7.6.1. Benzodiazepine
7.6.2. Non-Benzodiazepine
7.7. Cns Stimulant
7.7.1. Amphetamines
7.7.2. Methylphenidate
7.8. Hypnotic And Sedative
7.8.1. Barbiturates
7.8.2. Benzodiazepine
7.8.3. Non-Benzodiazepine Hypnotics
8. Central Nervous System Drugs Market, by Dosage Form
8.1. Introduction
8.2. Capsule
8.2.1. Extended-Release Capsule
8.2.2. Standard Capsule
8.3. Injectable Solution
8.3.1. IM
8.3.2. IV
8.3.3. Subcutaneous
8.4. Oral Solution
8.4.1. Suspension
8.4.2. Syrup
8.5. Tablet
8.5.1. Delayed-Release Tablet
8.5.2. Extended-Release Tablet
8.5.3. Standard Tablet
8.6. Transdermal Patch
8.6.1. Matrix Patch
8.6.2. Reservoir Patch
9. Central Nervous System Drugs Market, by Patient Type
9.1. Introduction
9.2. Adult
9.3. Geriatric
9.4. Pediatric
10. Central Nervous System Drugs Market, by Mechanism Of Action
10.1. Introduction
10.2. Cholinergic
10.3. Dopaminergic
10.4. Gabaergic
10.5. Glutamatergic
10.6. Noradrenergic
10.7. Serotonergic
11. Central Nervous System Drugs Market, by Therapeutic Area
11.1. Introduction
11.2. ADHD
11.3. Alzheimer's Disease
11.4. Anxiety
11.5. Depression
11.6. Epilepsy
11.7. Insomnia
11.8. Migraine
11.9. Pain
11.10. Parkinson's Disease
11.11. Schizophrenia
12. Central Nervous System Drugs Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacy
12.3. Online Pharmacy
12.4. Retail Pharmacy
13. Central Nervous System Drugs Market, by Prescription Type
13.1. Introduction
13.2. Over The Counter
13.3. Prescription
14. Central Nervous System Drugs Market, by Sales Model
14.1. Introduction
14.2. Branded
14.3. Generic
15. Central Nervous System Drugs Market, by Region
15.1. Asia-Pacific
15.2. Europe
15.3. North America
15.4. Latin America
15.5. Africa
15.6. Middle East
16. Central Nervous System Drugs Market, by Group
16.1. NATO
16.2. G7
16.3. BRICS
16.4. European Union
16.5. ASEAN
16.6. GCC
17. Central Nervous System Drugs Market, by Country
17.1. China
17.2. United States
17.3. Japan
17.4. India
17.5. Germany
17.6. United Kingdom
17.7. Australia
17.8. France
17.9. South Korea
17.10. Italy
17.11. Canada
17.12. Russia
17.13. Brazil
17.14. Mexico
17.15. Spain
18. Competitive Landscape
18.1. Market Share Analysis, 2025
18.2. FPNV Positioning Matrix, 2025
18.3. Market Concentration Analysis, 2025
18.3.1. Concentration Ratio (CR)
18.3.2. Herfindahl Hirschman Index (HHI)
18.4. Recent Developments & Impact Analysis, 2025
18.5. Product Portfolio Analysis, 2025
18.6. Benchmarking Analysis, 2025
19. Company Profiles
19.1. AbbVie Inc
19.2. Amatsigroup Co., Ltd.
19.3. Amgen Inc
19.4. AstraZeneca plc
19.5. Bayer AG
19.6. Biogen Inc
19.7. Boehringer Ingelheim International GmbH
19.8. Bristol-Myers Squibb Company
19.9. CMIC Group Co., Ltd.
19.10. Daiichi Sankyo Company, Limited
19.11. Eisai Co., Ltd.
19.12. Eli Lilly and Company
19.13. Evotec SE
19.14. F. Hoffmann-La Roche Ltd
19.15. GlaxoSmithKline plc
19.16. H. Lundbeck A/S
19.17. Johnson & Johnson Services, Inc
19.18. Lonza Group AG
19.19. Merck & Co., Inc
19.20. Merck KGaA
19.21. Neurocrine Biosciences, Inc
19.22. Novartis AG
19.23. Otsuka Pharmaceutical Co., Ltd
19.24. Patheon N.V.
19.25. Pfizer Inc
19.26. Recipharm AB
19.27. Samsung Biologics Co., Ltd.
19.28. Sanofi S.A.
19.29. Sumitomo Pharma Co., Ltd.
19.30. Takeda Pharmaceutical Company Ltd
19.31. Teva Pharmaceutical Industries Ltd
19.32. UCB S.A.
19.33. WuXi AppTec Co., Ltd.
List of Figures
FIGURE 1. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
FIGURE 7. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2032 (%)
FIGURE 9. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PATIENT TYPE, 2025 VS 2032 (%)
FIGURE 11. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2032 (%)
FIGURE 13. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2032 (%)
FIGURE 15. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 17. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2025 VS 2032 (%)
FIGURE 19. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SALES MODEL, 2025 VS 2032 (%)
FIGURE 21. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SALES MODEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 23. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 25. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 27. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 29. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL ANALGESIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL ANALGESIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL ANALGESIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL NON-OPIOID ANALGESIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL NON-OPIOID ANALGESIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL NON-OPIOID ANALGESIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL OPIOID ANALGESIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL OPIOID ANALGESIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL OPIOID ANALGESIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL ANTIDEPRESSANT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL ANTIDEPRESSANT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL ANTIDEPRESSANT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL ANTIEPILEPTIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL ANTIEPILEPTIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL ANTIEPILEPTIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL CALCIUM CHANNEL BLOCKER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL CALCIUM CHANNEL BLOCKER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL CALCIUM CHANNEL BLOCKER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL GABA ENHANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL GABA ENHANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL GABA ENHANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL GLUTAMATE INHIBITOR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL GLUTAMATE INHIBITOR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL GLUTAMATE INHIBITOR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL SODIUM CHANNEL BLOCKER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL SODIUM CHANNEL BLOCKER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL SODIUM CHANNEL BLOCKER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL ANTIPSYCHOTIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL ANTIPSYCHOTIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL ANTIPSYCHOTIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL ATYPICAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL ATYPICAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL ATYPICAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL TYPICAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL TYPICAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL TYPICAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL ANXIOLYTIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL ANXIOLYTIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL ANXIOLYTIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL BENZODIAZEPINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL BENZODIAZEPINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL BENZODIAZEPINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL NON-BENZODIAZEPINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL NON-BENZODIAZEPINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL NON-BENZODIAZEPINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL CNS STIMULANT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL CNS STIMULANT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL CNS STIMULANT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL AMPHETAMINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL AMPHETAMINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL AMPHETAMINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL METHYLPHENIDATE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL METHYLPHENIDATE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL METHYLPHENIDATE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL HYPNOTIC AND SEDATIVE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL HYPNOTIC AND SEDATIVE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL HYPNOTIC AND SEDATIVE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL BARBITURATES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL BARBITURATES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL BARBITURATES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL BENZODIAZEPINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL BENZODIAZEPINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL BENZODIAZEPINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL NON-BENZODIAZEPINE HYPNOTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL NON-BENZODIAZEPINE HYPNOTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL NON-BENZODIAZEPINE HYPNOTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL CAPSULE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL CAPSULE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL CAPSULE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL EXTENDED-RELEASE CAPSULE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL EXTENDED-RELEASE CAPSULE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL EXTENDED-RELEASE CAPSULE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL STANDARD CAPSULE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL STANDARD CAPSULE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL STANDARD CAPSULE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL INJECTABLE SOLUTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL INJECTABLE SOLUTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL INJECTABLE SOLUTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL IM MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL IM MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL IM MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL IV MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL IV MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL IV MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL ORAL SOLUTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL ORAL SOLUTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL ORAL SOLUTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL SUSPENSION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL SUSPENSION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL SUSPENSION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL SYRUP MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL SYRUP MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL SYRUP MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL TABLET MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL TABLET MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL TABLET MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL DELAYED-RELEASE TABLET MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL DELAYED-RELEASE TABLET MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL DELAYED-RELEASE TABLET MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL EXTENDED-RELEASE TABLET MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL EXTENDED-RELEASE TABLET MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL EXTENDED-RELEASE TABLET MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL STANDARD TABLET MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL STANDARD TABLET MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL STANDARD TABLET MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL TRANSDERMAL PATCH MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL TRANSDERMAL PATCH MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 115. GLOBAL TRANSDERMAL PATCH MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 116. GLOBAL MATRIX PATCH MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 117. GLOBAL MATRIX PATCH MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 118. GLOBAL MATRIX PATCH MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 119. GLOBAL RESERVOIR PATCH MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 120. GLOBAL RESERVOIR PATCH MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 121. GLOBAL RESERVOIR PATCH MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 122. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 123. GLOBAL ADULT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 124. GLOBAL ADULT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 125. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 126. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 127. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 128. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 129. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 130. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 131. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 132. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 133. GLOBAL CHOLINERGIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 134. GLOBAL CHOLINERGIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 135. GLOBAL CHOLINERGIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 136. GLOBAL DOPAMINERGIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 137. GLOBAL DOPAMINERGIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 138. GLOBAL DOPAMINERGIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 139. GLOBAL GABAERGIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 140. GLOBAL GABAERGIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 141. GLOBAL GABAERGIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 142. GLOBAL GLUTAMATERGIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 143. GLOBAL GLUTAMATERGIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 144. GLOBAL GLUTAMATERGIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 145. GLOBAL NORADRENERGIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 146. GLOBAL NORADRENERGIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 147. GLOBAL NORADRENERGIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 148. GLOBAL SEROTONERGIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 149. GLOBAL SEROTONERGIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 150. GLOBAL SEROTONERGIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 151. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 152. GLOBAL ADHD MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 153. GLOBAL ADHD MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 154. GLOBAL ADHD MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 155. GLOBAL ALZHEIMER'S DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 156. GLOBAL ALZHEIMER'S DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 157. GLOBAL ALZHEIMER'S DISEASE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 158. GLOBAL ANXIETY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 159. GLOBAL ANXIETY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 160. GLOBAL ANXIETY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 161. GLOBAL DEPRESSION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 162. GLOBAL DEPRESSION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 163. GLOBAL DEPRESSION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 164. GLOBAL EPILEPSY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 165. GLOBAL EPILEPSY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 166. GLOBAL EPILEPSY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 167. GLOBAL INSOMNIA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 168. GLOBAL INSOMNIA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 169. GLOBAL INSOMNIA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 170. GLOBAL MIGRAINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 171. GLOBAL MIGRAINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 172. GLOBAL MIGRAINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 173. GLOBAL PAIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 174. GLOBAL PAIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 175. GLOBAL PAIN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 176. GLOBAL PARKINSON'S DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 177. GLOBAL PARKINSON'S DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 178. GLOBAL PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 179. GLOBAL SCHIZOPHRENIA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 180. GLOBAL SCHIZOPHRENIA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 181. GLOBAL SCHIZOPHRENIA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 182. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 183. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 184. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 185. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 186. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 187. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 188. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 189. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 190. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 191. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 192. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2017-2032 (USD MILLION)
TABLE 193. GLOBAL OVER THE COUNTER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 194. GLOBAL OVER THE COUNTER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 195. GLOBAL OVER THE COUNTER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 196. GLOBAL PRESCRIPTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 197. GLOBAL PRESCRIPTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 198. GLOBAL PRESCRIPTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 199. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SALES MODEL, 2017-2032 (USD MILLION)
TABLE 200. GLOBAL BRANDED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 201. GLOBAL BRANDED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 202. GLOBAL BRANDED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 203. GLOBAL GENERIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 204. GLOBAL GENERIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 205. GLOBAL GENERIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 206. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 207. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 208. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 209. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANALGESIC, 2017-2032 (USD MILLION)
TABLE 210. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIEPILEPTIC, 2017-2032 (USD MILLION)
TABLE 211. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIPSYCHOTIC, 2017-2032 (USD MILLION)
TABLE 212. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANXIOLYTIC, 2017-2032 (USD MILLION)
TABLE 213. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CNS STIMULANT, 2017-2032 (USD MILLION)
TABLE 214. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY HYPNOTIC AND SEDATIVE, 2017-2032 (USD MILLION)
TABLE 215. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 216. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CAPSULE, 2017-2032 (USD MILLION)
TABLE 217. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY INJECTABLE SOLUTION, 2017-2032 (USD MILLION)
TABLE 218. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ORAL SOLUTION, 2017-2032 (USD MILLION)
TABLE 219. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TABLET, 2017-2032 (USD MILLION)
TABLE 220. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TRANSDERMAL PATCH, 2017-2032 (USD MILLION)
TABLE 221. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 222. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 223. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 224. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 225. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2017-2032 (USD MILLION)
TABLE 226. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SALES MODEL, 2017-2032 (USD MILLION)
TABLE 227. EUROPE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 228. EUROPE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 229. EUROPE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANALGESIC, 2017-2032 (USD MILLION)
TABLE 230. EUROPE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIEPILEPTIC, 2017-2032 (USD MILLION)
TABLE 231. EUROPE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIPSYCHOTIC, 2017-2032 (USD MILLION)
TABLE 232. EUROPE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANXIOLYTIC, 2017-2032 (USD MILLION)
TABLE 233. EUROPE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CNS STIMULANT, 2017-2032 (USD MILLION)
TABLE 234. EUROPE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY HYPNOTIC AND SEDATIVE, 2017-2032 (USD MILLION)
TABLE 235. EUROPE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 236. EUROPE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CAPSULE, 2017-2032 (USD MILLION)
TABLE 237. EUROPE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY INJECTABLE SOLUTION, 2017-2032 (USD MILLION)
TABLE 238. EUROPE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ORAL SOLUTION, 2017-2032 (USD MILLION)
TABLE 239. EUROPE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TABLET, 2017-2032 (USD MILLION)
TABLE 240. EUROPE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TRANSDERMAL PATCH, 2017-2032 (USD MILLION)
TABLE 241. EUROPE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 242. EUROPE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 243. EUROPE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 244. EUROPE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 245. EUROPE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2017-2032 (USD MILLION)
TABLE 246. EUROPE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SALES MODEL, 2017-2032 (USD MILLION)
TABLE 247. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 248. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 249. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANALGESIC, 2017-2032 (USD MILLION)
TABLE 250. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIEPILEPTIC, 2017-2032 (USD MILLION)
TABLE 251. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIPSYCHOTIC, 2017-2032 (USD MILLION)
TABLE 252. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANXIOLYTIC, 2017-2032 (USD MILLION)
TABLE 253. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CNS STIMULANT, 2017-2032 (USD MILLION)
TABLE 254. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY HYPNOTIC AND SEDATIVE, 2017-2032 (USD MILLION)
TABLE 255. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 256. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CAPSULE, 2017-2032 (USD MILLION)
TABLE 257. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY INJECTABLE SOLUTION, 2017-2032 (USD MILLION)
TABLE 258. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ORAL SOLUTION, 2017-2032 (USD MILLION)
TABLE 259. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TABLET, 2017-2032 (USD MILLION)
TABLE 260. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TRANSDERMAL PATCH, 2017-2032 (USD MILLION)
TABLE 261. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 262. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 263. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 264. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 265. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2017-2032 (USD MILLION)
TABLE 266. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SALES MODEL, 2017-2032 (USD MILLION)
TABLE 267. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 268. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 269. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANALGESIC, 2017-2032 (USD MILLION)
TABLE 270. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIEPILEPTIC, 2017-2032 (USD MILLION)
TABLE 271. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIPSYCHOTIC, 2017-2032 (USD MILLION)
TABLE 272. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANXIOLYTIC, 2017-2032 (USD MILLION)
TABLE 273. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CNS STIMULANT, 2017-2032 (USD MILLION)
TABLE 274. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY HYPNOTIC AND SEDATIVE, 2017-2032 (USD MILLION)
TABLE 275. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 276. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CAPSULE, 2017-2032 (USD MILLION)
TABLE 277. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY INJECTABLE SOLUTION, 2017-2032 (USD MILLION)
TABLE 278. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ORAL SOLUTION, 2017-2032 (USD MILLION)
TABLE 279. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TABLET, 2017-2032 (USD MILLION)
TABLE 280. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TRANSDERMAL PATCH, 2017-2032 (USD MILLION)
TABLE 281. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 282. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 283. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 284. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 285. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2017-2032 (USD MILLION)
TABLE 286. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SALES MODEL, 2017-2032 (USD MILLION)
TABLE 287. AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 288. AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 289. AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANALGESIC, 2017-2032 (USD MILLION)
TABLE 290. AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIEPILEPTIC, 2017-2032 (USD MILLION)
TABLE 291. AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIPSYCHOTIC, 2017-2032 (USD MILLION)
TABLE 292. AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANXIOLYTIC, 2017-2032 (USD MILLION)
TABLE 293. AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CNS STIMULANT, 2017-2032 (USD MILLION)
TABLE 294. AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY HYPNOTIC AND SEDATIVE, 2017-2032 (USD MILLION)
TABLE 295. AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 296. AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CAPSULE, 2017-2032 (USD MILLION)
TABLE 297. AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY INJECTABLE SOLUTION, 2017-2032 (USD MILLION)
TABLE 298. AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ORAL SOLUTION, 2017-2032 (USD MILLION)
TABLE 299. AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TABLET, 2017-2032 (USD MILLION)
TABLE 300. AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TRANSDERMAL PATCH, 2017-2032 (USD MILLION)
TABLE 301. AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 302. AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 303. AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 304. AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 305. AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2017-2032 (USD MILLION)
TABLE 306. AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SALES MODEL, 2017-2032 (USD MILLION)
TABLE 307. MIDDLE EAST CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 308. MIDDLE EAST CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 309. MIDDLE EAST CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANALGESIC, 2017-2032 (USD MILLION)
TABLE 310. MIDDLE EAST CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIEPILEPTIC, 2017-2032 (USD MILLION)
TABLE 311. MIDDLE EAST CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIPSYCHOTIC, 2017-2032 (USD MILLION)
TABLE 312. MIDDLE EAST CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANXIOLYTIC, 2017-2032 (USD MILLION)
TABLE 313. MIDDLE EAST CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CNS STIMULANT, 2017-2032 (USD MILLION)
TABLE 314. MIDDLE EAST CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY HYPNOTIC AND SEDATIVE, 2017-2032 (USD MILLION)
TABLE 315. MIDDLE EAST CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 316. MIDDLE EAST CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CAPSULE, 2017-2032 (USD MILLION)
TABLE 317. MIDDLE EAST CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY INJECTABLE SOLUTION, 2017-2032 (USD MILLION)
TABLE 318. MIDDLE EAST CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ORAL SOLUTION, 2017-2032 (USD MILLION)
TABLE 319. MIDDLE EAST CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TABLET, 2017-2032 (USD MILLION)
TABLE 320. MIDDLE EAST CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TRANSDERMAL PATCH, 2017-2032 (USD MILLION)
TABLE 321. MIDDLE EAST CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 322. MIDDLE EAST CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 323. MIDDLE EAST CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 324. MIDDLE EAST CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 325. MIDDLE EAST CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2017-2032 (USD MILLION)
TABLE 326. MIDDLE EAST CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SALES MODEL, 2017-2032 (USD MILLION)
TABLE 327. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 328. NATO CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 329. NATO CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 330. NATO CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANALGESIC, 2017-2032 (USD MILLION)
TABLE 331. NATO CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIEPILEPTIC, 2017-2032 (USD MILLION)
TABLE 332. NATO CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIPSYCHOTIC, 2017-2032 (USD MILLION)
TABLE 333. NATO CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANXIOLYTIC, 2017-2032 (USD MILLION)
TABLE 334. NATO CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CNS STIMULANT, 2017-2032 (USD MILLION)
TABLE 335. NATO CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY HYPNOTIC AND SEDATIVE, 2017-2032 (USD MILLION)
TABLE 336. NATO CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 337. NATO CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CAPSULE, 2017-2032 (USD MILLION)
TABLE 338. NATO CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY INJECTABLE SOLUTION, 2017-2032 (USD MILLION)
TABLE 339. NATO CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ORAL SOLUTION, 2017-2032 (USD MILLION)
TABLE 340. NATO CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TABLET, 2017-2032 (USD MILLION)
TABLE 341. NATO CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TRANSDERMAL PATCH, 2017-2032 (USD MILLION)
TABLE 342. NATO CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 343. NATO CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 344. NATO CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 345. NATO CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 346. NATO CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2017-2032 (USD MILLION)
TABLE 347. NATO CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SALES MODEL, 2017-2032 (USD MILLION)
TABLE 348. G7 CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 349. G7 CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 350. G7 CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANALGESIC, 2017-2032 (USD MILLION)
TABLE 351. G7 CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIEPILEPTIC, 2017-2032 (USD MILLION)
TABLE 352. G7 CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIPSYCHOTIC, 2017-2032 (USD MILLION)
TABLE 353. G7 CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANXIOLYTIC, 2017-2032 (USD MILLION)
TABLE 354. G7 CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CNS STIMULANT, 2017-2032 (USD MILLION)
TABLE 355. G7 CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY HYPNOTIC AND SEDATIVE, 2017-2032 (USD MILLION)
TABLE 356. G7 CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 357. G7 CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CAPSULE, 2017-2032 (USD MILLION)
TABLE 358. G7 CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY INJECTABLE SOLUTION, 2017-2032 (USD MILLION)
TABLE 359. G7 CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ORAL SOLUTION, 2017-2032 (USD MILLION)
TABLE 360. G7 CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TABLET, 2017-2032 (USD MILLION)
TABLE 361. G7 CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TRANSDERMAL PATCH, 2017-2032 (USD MILLION)
TABL

Companies Mentioned

  • AbbVie Inc
  • Amatsigroup Co., Ltd.
  • Amgen Inc
  • AstraZeneca plc
  • Bayer AG
  • Biogen Inc
  • Boehringer Ingelheim International GmbH
  • Bristol‑Myers Squibb Company
  • CMIC Group Co., Ltd.
  • Daiichi Sankyo Company, Limited
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Evotec SE
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc
  • H. Lundbeck A/S
  • Johnson & Johnson Services, Inc
  • Lonza Group AG
  • Merck & Co., Inc
  • Merck KGaA
  • Neurocrine Biosciences, Inc
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd
  • Patheon N.V.
  • Pfizer Inc
  • Recipharm AB
  • Samsung Biologics Co., Ltd.
  • Sanofi S.A.
  • Sumitomo Pharma Co., Ltd.
  • Takeda Pharmaceutical Company Ltd
  • Teva Pharmaceutical Industries Ltd
  • UCB S.A.
  • WuXi AppTec Co., Ltd.

Table Information

Report AttributeDetails
No. of Pages186
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 34.16 Billion
Forecasted Market Value ( USD ) by 2032 $ 63.59 Billion
Compound Annual Growth Rate10.8%
Regions CoveredGlobal
No. of Companies Mentioned33

Related Topics

Related Reports

Central Nervous System Therapeutics Market - Global Forecast 2026-2032 - Product Image

Central Nervous System Therapeutics Market - Global Forecast 2026-2032

  • Report
  • 184 Pages
  • Global
From
Ependymoma Drug Market - Global Forecast 2026-2032 - Product Image

Ependymoma Drug Market - Global Forecast 2026-2032

  • Report
  • 192 Pages
  • Global
From
Central Nervous System Therapeutics Market Size, Share & Trends Analysis Report by Disease, Drug Class, Distribution Channel, Region, and Segment Forecasts, 2026-2033 - Product Image

Central Nervous System Therapeutics Market Size, Share & Trends Analysis Report by Disease, Drug Class, Distribution Channel, Region, and Segment Forecasts, 2026-2033

  • Report
  • 150 Pages
  • Global
From
Generic Central Nervous System Drugs Market Report 2026 - Product Image

Generic Central Nervous System Drugs Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Central Nervous System Therapeutics Market - Global Strategic Business Report - Product Image

Central Nervous System Therapeutics Market - Global Strategic Business Report

  • Report
  • 395 Pages
  • Global
From

About the Central Nervous System Drugs Market

The Central Nervous System Drugs market is a sector of the pharmaceutical industry that focuses on the development and production of drugs that target the central nervous system. These drugs are used to treat a variety of conditions, including neurological disorders, mental health issues, and pain management. The market is composed of a variety of companies, ranging from large multinationals to small start-ups. The Central Nervous System Drugs market is highly competitive, with companies competing to develop the most effective and safe treatments. Companies in the market are constantly researching and developing new drugs, as well as improving existing treatments. Many of these companies are also involved in clinical trials to test the safety and efficacy of their products. Some of the major companies in the Central Nervous System Drugs market include Pfizer, GlaxoSmithKline, Merck, Novartis, and Johnson & Johnson. These companies are involved in the development and production of a wide range of CNS drugs, including antidepressants, antipsychotics, and anticonvulsants. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.